- $1.85bn
- $1.71bn
- 32
- 22
- 82
- 42
Annual balance sheet for Belite Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 25.6 | 17.3 | 42.1 | 88.2 | 145 |
| Net Total Receivables | 0.04 | 0.023 | 0.019 | 0.867 | 0.594 |
| Prepaid Expenses | |||||
| Total Current Assets | 25.7 | 17.4 | 42.8 | 89.9 | 147 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.046 | 0.094 | 1.35 | 1.3 | 0.965 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 25.7 | 18.3 | 44.3 | 94.6 | 152 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.972 | 1.64 | 2.1 | 3.63 | 6.05 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.972 | 1.64 | 2.77 | 4.21 | 6.31 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 24.8 | 16.7 | 41.5 | 90.4 | 146 |
| Total Liabilities & Shareholders' Equity | 25.7 | 18.3 | 44.3 | 94.6 | 152 |
| Total Common Shares Outstanding |